Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $9.33, but opened at $10.79. Ono Pharmaceutical shares last traded at $10.79, with a volume of 446 shares changing hands.
Ono Pharmaceutical Price Performance
The company has a debt-to-equity ratio of 0.13, a current ratio of 3.07 and a quick ratio of 2.56. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of 15.41 and a beta of 0.49. The firm has a 50 day simple moving average of $10.47 and a two-hundred day simple moving average of $10.54.
About Ono Pharmaceutical
(
Get Free Report)
Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.
Recommended Stories
Before you consider Ono Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ono Pharmaceutical wasn't on the list.
While Ono Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
